Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Halozyme posts record revenue in 2022, eyes growth opportunities

Halozyme's strong financial performance in 2022 and positive revenue guidance for 2023 reflect a robust growth trajectory.
While facing integration challenges from acquisitions and potential competition, the company's strategic priorities and market engagement remain strong.
Exploring new collaborations, advancing product development, and maintaining a competitive edge present key opportunities for Halozyme.
Overall, Halozyme's proactive approach to growth and market dynamics positions it well for future success in the biopharmaceutical industry.

Halozyme reports robust Q1 earnings, poised for continued growth

Halozyme's strong Q1 performance and robust pipeline position them for continued revenue growth and leadership in subcutaneous drug delivery.
Challenges include regulatory impacts and legal uncertainties, but opportunities in new agreements, partnerships, and investments offer avenues for future growth.
Overall, Halozyme's strategic focus on innovation and revenue diversification bodes well for their long-term success and financial stability.

Halozyme reports robust Q2 growth, eyes new partnerships for revenue

Halozyme's Q2 2023 earnings call showcased strong financial performance, innovative product developments, and a positive outlook for revenue growth. The company's focus on expanding partnerships, maintaining revenue durability, and strategic capital allocation positions it well for future success in the biopharmaceutical market.

Halozyme excels in Q3, raises guidance, eyes market expansion

Halozyme's Q3 performance reflects financial strength and operational resilience, supported by strategic partnerships and revenue growth.
The company's focus on shareholder value through accelerated buybacks and commitment to innovation positions them for sustained success.
While challenges like market competition exist, Halozyme's opportunities in market expansion and revenue growth paint a positive outlook for the future.

Halozyme posts record earnings, eyes strategic growth opportunities ahead

Halozyme's strong financial results and positive outlook for 2024 position the company for continued growth and value creation.
Addressing challenges around market adoption and reimbursement processes will be key to unlocking the full potential of subcutaneous products.
Strategic partnerships, new product launches, and a focus on shareholder value enhancement underscore Halozyme's commitment to sustainable growth.

Halozyme reports robust Q1 growth, navigates biosimilar challenges

Halozyme's Q1 2024 performance demonstrated strong financial growth driven by royalties and milestone payments, supported by operational achievements and strategic capital allocation.
While facing challenges such as biosimilar competition and partnership complexities, the company remains well-positioned to capitalize on opportunities in subcutaneous delivery preferences and market expansion.
Overall, Halozyme's focus on revenue diversification, partnership expansion, and operational excellence sets a positive trajectory for sustained growth and resilience in the biopharmaceutical sector.

Halozyme posts strong Q3 results, raises guidance amid growth opportunities

Halozyme Therapeutics reported a stellar Q3 performance with significant revenue growth and raised guidance across key financial metrics. The company's partnerships, product portfolio, and strong financial position underscore its growth potential and market resilience. Halozyme is well-positioned to capitalize on opportunities for expansion and innovation in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2019 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates

Halozyme Suffers Pancreatic Cancer Trial Failure, Technology Platform Will Keep It Afloat

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Shares of the actively traded, smid-cap Halozyme Therapeutics, Inc. (NASDAQ: HALO) were slipping Monday in reaction to an adverse clinical readout.

Halozyme Scraps Oncology Program Following Failed Study, Charts Out Profitability Plan

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2019 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 41.18% and -0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates

Earnings Preview: Halozyme Therapeutics (HALO) Q2 Earnings Expected to Decline

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2019 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates

Find out why these oncology-focused companies stand out as great opportunities right now.

News for Halozyme Therapeutics Stock (HALO)